Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHI) and a pioneer in science-based sleep solutions, today announces a significant advancement in sleep therapy with the commercial release of a first of its kind minimal contact nasal mask – Wisp. Designed to fit more than 98% of sleep apnea patients, Wisp brings distinctive styling and patented technology for a better overall mask experience that may improve patient compliance.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62230-philips-respironics-announces-advancement-in-sleep-therapy-with-wisp
Philips Respironics, a unit of Royal Philips Electronics (NYSE: PHG, AEX: PHI), is introducing its latest advancement in oxygen therapy. SimplyGo is the only portable oxygen concentrator (POC) to offer continuous flow (up to 2 liters per minute) and pulse-dose delivery in a single device weighing 10 pounds or less. With this combination of capabilities, the SimplyGo POC helps homecare providers manage the therapy and lifestyle needs of nearly all oxygen users.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54713-philips-respironics-simplygo-portable-oxygen-concentrator
Philips Respironics, a unit of Royal Philips (NYSE: PHG, AEX: PHIA) and a pioneer in science-based sleep solutions, brings a new comfort option to its best-selling, most comfortable full face mask that fits most patients. The Amara gel cushion option is part of a groundbreaking series of new masks and services that are setting a new standard for patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64501-philips-respironics-amara-gel-cushion-face-mask-sleep-apnea
Boston Scientific Corporation (NYSE: BSX) introduces its CardioTeach™ iPad® app, an industry-first, free educational resource to help healthcare professionals better educate patients and caregivers about therapy options related to cardiovascular and peripheral diseases, specifically atrial and ventricular arrhythmias, coronary artery disease, heart failure, heart rhythm disorders and peripheral vascular disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/43509-boston-scientific-cardioteach-ipad-app
Madison Taliaferro spent weeks in the hospital in 2012. After a decade of suffering from cystic fibrosis, she underwent a double lung transplant. She powered through the difficult surgery and the recovery that followed –long days of physical therapy and rehabilitation. Her parents were there. Her best friend visited from Kansas. Grandparents rotated shifts so she was never alone. But one request still lingered.
“I just wanted to see my dogs,” she remembers.
Having suffered from the effects of chronic illness for the decade prior, Madison was no stranger to long days at home, isolated from the school germs that could turn her illness into a critical condition with a single sneeze. When her friends couldn’t visit, her dogs were there. But at the hospital, they weren’t.
To view the multimedia release go to:
http://www.multivu.com/players/English/7835951-purina-family-pet-center-st-louis-childrens/
Boston Scientific Corporation (NYSE: BSX) announces positive clinical data from the Research in Severe Asthma (RISA) Trial, demonstrating the long-term safety of bronchial thermoplasty (BT) in patients treated with the Company’s AlairTM Bronchial Thermoplasty System. Follow-up data demonstrate that stable lung function is maintained and late clinical complications are absent over a five-year period in patients with severe refractory asthma treated with BT. Results were presented today at the annual European Respiratory Society (ERS) Congress in Amsterdam by Michel Laviolette, M.D., Professor of Medicine, Institut universitaire de cardiologie et de pneumologie at Université Laval in Québec City, Canada.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/bostonscientific/52128/
InSightec Ltd, the leader in magnetic resonance imaging (MRI)-guided Focused Ultrasound therapy, announced that the U.S. Food and Drug Administration (FDA) has approved ExAblate® MRI-guided focused ultrasound as a therapy to treat pain from bone metastases in patients who do not respond or cannot undergo radiation treatment for their pain. This is the second FDA approval for ExAblate, which has been used widely since it was approved in 2004 as a non-invasive, outpatient, therapy for uterine fibroids.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56632-insightec-fda-approves-exablate
Pet owner Judy Bernath loves her 11-year-old cat Billy, so when she noticed he had become lethargic, started losing weight and drastically changed from the happy cat he had once been, she made a visit to see her veterinarian Dr. David Bruyette, medical director at VCA West Los Angeles Animal Hospital. The VCA team diagnosed Billy as being hyperthyroid within a few days, and Dr. Bruyette shared conventional therapy options with Judy, like radiation therapy, daily pharmaceuticals and surgery. In addition, he discussed and ultimately recommended a new and different approach for Billy’s case – nutritional management.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51765-hills-pet-nutrition-launches-new-pet-food-for-hyperthyroid-cats
Using a combination of 160 high-resolution tungsten leaves and dramatically faster leaf movement, Elekta’s revolutionary new Agility™* MLC promises a new level of precision and delivery speed in radiation therapy treatments for cancer patients. Elekta recently received 510(k) clearance (K121328) from the U.S. Food and Drug Administration (FDA) for Agility, enabling U.S. medical centers to provide these clinical benefits to their patients with cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55638-elekta-agility-radiation-therapy-radiotherapy-cancer-sbrt
Forget all your worries and refresh your mood with relaxing music and get peaceful sleep with sleep music here. Try our soothing music and experience its magic.http://www.easysleepmusic.com
